In silico experiments of existing and hypothetical cytokine-directed clinical trials using agent-based modeling

Critical Care Medicine

Volumn 32, Issue 10, 2004, Pages 2050-2060

  An, Gary ^a  

^a Jr Hospital of Cook County   (United States)

Author keywords

Complexity theory; Computer simulation; Cytokines; Mathematical modeling; Multiple organ failure; Sepsis; Systemic inflammatory response syndrome

Indexed keywords

CD11 ANTIGEN; CD18 ANTIGEN; CELL RECEPTOR; CYTOKINE; CYTOKINE ANTIBODY; ENDOTOXIN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 8; L SELECTIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD18; PADGEM PROTEIN; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

COMPUTER SIMULATION; CYTOKINE RELEASE; ENDOTHELIUM CELL; HUMAN; IMMUNE RESPONSE; MATHEMATICAL MODEL; MONOCYTE; MORTALITY; MULTIPLE ORGAN FAILURE; NEUTROPHIL; PRIORITY JOURNAL; REVIEW; SEPSIS; STATISTICAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

CLINICAL TRIALS; COMPUTER SIMULATION; CYTOKINES; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNITY, NATURAL; MODELS, THEORETICAL; MULTIPLE ORGAN FAILURE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 4744344132     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000139707.13729.7D     Document Type: Review

References (45)

1. Cohen, J, Carlet, JC, for the INTERSEPT Study Group: INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med 1996; 24:1531-1439
2. Reinhart K, Menges T, Gardlund B, et al: Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med 2001; 29:765-769
3. Opal SM, Fisher CJ, Dhainaut JF, et al: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997; 25:1115-1123
4. Rhee P, Morris J, Durham R, et al: Recombinant humanized monoclonal antibody against CD18 (rhuMab CD18) in traumatic hemorrhagic shock: Results of a phase II clinical trial. J Trauma 2000; 49:611-620
5. Fisher CJ, Dhainaut J-FA, Opal SM, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo-controlled trial. JAMA 1994; 271:1836-1843
6. Fisher CJ, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996; 334:1697-1702
7. Abraham E, Glauser MP, Butler T, et al: p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: A randomized controlled multicenter trial. JAMA 1997; 277:1531-1538
8. Abraham E, Anzueto A, Gutierrez G, et al: Double-blind randomised controlled trial of monoclonal antibody to human tumor necrosis factor in the treatment of septic shock. Lancet 1998; 351:929-933
9. Abraham E, Laterre, P-F, Garbino J, et al: Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001; 29:503-510
10. Root RK, Lodato RF, Patrick W, et al: Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003; 312:367-373
11. Bernard GR, Vincent, J-L, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
12. Cohen, J: Adjunctive therapy in sepsis: A critical analysis of the clinical trial programme. Br Med Bull 1999; 55:212-225
13. Zeni F, Freeman B, Natanson C: Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 1997; 25:1095-1100
14. Vincent J-L: Search for effective immuno-modulating strategies against sepsis. Lancet 1998; 351:922-923
15. Marshall, JC: Clinical trials of mediator-directed therapy in sepsis: What have we learned? Intensive Care Med 2000; 26:875-883
16. Godin PJ, Buchman TG: Uncoupling of biologic oscillators: A complementary hypothesis concerning the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 1996; 24:1107-1116
17. Buchman TG: Physiologic stability and physiologic state. J Trauma 1996; 41:599-605
18. Seely AJE, Christou NV: Multiple organ dysfunction syndrome: Exploring the paradigm of complex nonlinear systems. Crit Care Med 2000; 28:2193-2200
19. Marshall JC: Complexity, chaos, and incomprehensibility: Parsing the biology of critical illness. Crit Care Med 2000; 28:2646-2648
20. Buchman TG, Cobb JP, Lapedes AS, et al: Complex systems analysis: A tool for shock research. Shock 2001; 16:248-251
21. Neugebauer EAM, Willy C, Sauerland S: Complexity and non-linearity in shock research: Reductionism or synthesis? Shock 2001; 16:252-258
22. Tjardes T, Neugebauer EAM: Sepsis research in the next millennium: Concentrate on the software rather than the hardware. Shock 2002; 17:1-8
23. An GC: Complexity theory and surgery: Integrating a new analytical paradigm. New Surgery 2001; 1:148-152
24. An GC: Agent-based computer simulation and SIRS: Building a bridge between basic science and clinical trials. Shock 2001; 14:266-273
25. Neugebauer EA, Holaday JW (Eds): Handbook of Mediators in Septic Shock. Boca Raton, FL, CRC Press, 1993
26. Oberholzer A, Oberholzer C, Moldawer L: Cytokine signaling-Regulation of the immune response in normal and critically ill states. Crit Care Med 2000; 28S:N3-N12
27. Maier RV, Bolger EM: Endothelial changes after shock and injury. New Horiz 1996; 4:211-223
28. Aird WC: Endothelial cells dynamics and complexity theory. Crit Care Med 2002; 30S:S180-S185
29. Gaviria JM, Dale DC, Root, RK: Neutrophils: Function and role in sepsis syndrome. Sepsis 1998; 2:107-117
30. Romaschin AD, Foster DM, Walker PM, et al: Let the cells speak: Neutrophils as biologic markers of the inflammatory response. Sepsis 1998; 2:119-125
31. Partrick DA, Moore FA, Moore EE, et al: Neutrophil priming and activation in the pathogenesis of postinjury multiple organ failure. New Horiz 1996; 4:194-210
32. Hauser CJ: Regional macrophage activation after injury and the compartmentalization of inflammation in trauma. New Horiz 1996; 4:235-251
33. Schlag G, Redl, H: Mediators of injury and inflammation. World J Surg 1996; 20:406-410
34. Faist E, Schinkel C, Zimmer S: Update on the mechanism of immune suppression of injury and immune modulation. World J Surg 1996; 20:454-459
35. Cavaillon J: Pathophysiological role of pro- and anti-inflammatory cytokines in sepsis. Sepsis 1998; 2:127-140
36. Guirao X, Lowry SF: Biologic control of injury and inflammation: Much more than too little or too late. World J Surg 1996; 20:437-446
37. Martinez-Mier G, Toledo-Pereyra LH, Ward, PA: Adhesion molecules and hemorrhagic shock. J Trauma 2001; 51:408-415
38. Mahidhara R, Billiar TR: Apoptosis in sepsis. Crit Care Med 2000; 28S:N105-N113
39. Gabrilove, JL: Introduction and overview of hematopoietic growth factors. Sem Hematol 1989; 26S:1-4
40. Al Kharfy KM, Kellum JA, Matzke GR: Unintended Immunomodulation: Part I. Effects of common clinical conditions on cytokine bio-synthesis. Shock 2000; 13:333-345
41. Harlan JM, Winn RK: Leukocyte-endothelial interactions: Clinical trials of anti-adhesion therapy. Crit Care Med 2002; 30S:S214-S219
42. StarlogoT Website. Available at: http://www.ccl.sesp.northwestern.edu/cm/ starlogoT/
43. Auyang SY: Foundations of Complex-System Theories in Economics, Evolutionary Biology and Statistical Physics. Cambridge, UK, Cambridge University Press, 1998
44. Railsback SF: Getting "results": The pattern-oriented approach to analyzing natural systems with individual-based models. Natural Resource Modeling 2001; 14:465-474
45. Remick DG, Call DR, Ebong SJ, et al: Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality. Crit Care Med 2001; 29:473-481